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Abstract: In patients with hypertension, 24-hour blood pressure control is the major therapeu-
tic goal. The number of daily doses is one characteristic of an antihypertensive agent that may 
affect the adequacy of 24-hour control. One measure of therapeutic coverage is the 24-hour 
trough-to-peak ratio, which determines the suitability of an agent for once-daily administration. 
The closer an agent is to a 100% trough-to-peak ratio, the more uniform the 24-hour coverage 
and therefore blood pressure control. High trough-to-peak ratio, long-acting antihypertensive 
medications lower blood pressure more gradually, which reduces the likelihood of adverse 
events attributable to abrupt drug action that occurs with shorter-acting agents. In hypertension, 
the natural diurnal variation of blood pressure may be altered, including elevated nighttime 
  pressures. An optimal once-daily hypertension therapy would not only lower blood pressure but 
also normalize any blunted circadian variations in blood pressure. The benefits of once-daily 
agents with sustained therapeutic coverage may also be explained, in part, by increased patient 
adherence to simpler regimens as well as lower loss of blood pressure control during virtually   
inevitable intermittent noncompliance. Studies have demonstrated that once-daily antihyper-
tensive agents have the highest adherence compared with twice-daily or multiple daily doses, 
including greater adherence to the prescribed timing of doses.
Keywords: adherence, blood pressure control, therapeutic coverage
Introduction
Current guidelines recommend antihypertensive therapies by class, taking into consid-
eration the overall efficacy and safety profiles of the agents in each class.1,2 However, 
individual agents or subgroups of agents may need to be considered separately in 
classes that are very heterogeneous, such as diuretics, calcium channel blockers, and 
β-adrenergic blockers. One important drug characteristic is the duration of therapeutic 
coverage, which influences the required number of daily doses as well as the adequacy 
of blood pressure (BP) control, especially at the end of the once-daily dosing intervals 
(just before the next scheduled dose).
Therapeutic coverage of an antihypertensive agent equates to the amount of time 
BP is under control with a single dose.3 When an agent has a short therapeutic effect, 
multiple daily doses are necessary.3 The number of daily doses in an antihyperten-
sive regimen affects BP control by different means. A mistimed or missed dose, 
for example, may have clinically relevant consequences on BP control if the time 
between doses exceeds the period of therapeutic coverage.4 Moreover, adherence and 
compliance appear to be reduced with complex, multiple-dose regimens.5   Therefore, 
a   once-daily antihypertensive agent that provides genuine 24-hour BP control may Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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increase   adherence, resulting in improved efficacy and 
  long-term clinical outcomes.
Another important factor is how well the therapeutic 
coverage of different agents works in combination. Class 
combinations are useful in achieving BP goals, as the 
majority of patients will need two or more agents.1,2 In 
fact, guidelines recommend initiating antihypertensive 
treatment with two agents if patients are 20/10 mm Hg or 
15/10 mm Hg above their identified BP goal.1,2 However, 
therapeutic gaps in coverage resulting in uneven 24-hour 
BP control may occur from using multiple antihyper-
tensives with different lengths of therapeutic coverage, 
especially when adherence is irregular between individual 
agents.
This review will evaluate the available clinical evidence 
for 24-hour BP control with once-daily or multiple-daily 
dosing regimens. The effects of increasing the number of 
daily doses on adherence and BP control as well as reported 
intermediate clinical outcomes or BP effects of mistimed or 
missed doses will be evaluated.
Effect of increasing the number  
of daily antihypertensive doses  
on 24-hour BP control
In clinical studies, therapeutic coverage is reported as a 
percentage of the 24-hour period or as a placebo-corrected 
trough-to-peak ratio,3,6,7 and even when trough-to-peak ratios 
exceed 50%, the higher the better. The mean decrease in 
BP 24 hours after the antihypertensive dose is termed the 
trough, and the peak represents when the mean BP decrease 
is   maximal after receiving the antihypertensive agent.4 
  Therefore, the BP decrease at the trough is compared with 
the BP decrease at the peak. Values obtained with the anti-
hypertensive agent should be subtracted from placebo values 
when calculating the trough-to-peak ratio. The   trough-to-peak 
ratio provides a duration of action index for each antihyper-
tensive agent and identifies drug regimens that would provide 
adequate BP reductions at the end of the dose interval without 
risk of excessively lowering BP at its peak effect and result 
in adverse events such as hypotension.4,8 The United States 
Food and Drug Administration (FDA) recommended in 1990 
that the mean antihypertensive effect of an agent at trough 
compared with the effect at the agent’s therapeutic peak 
was to be at least 50%.4,8,9 If an agent studied with once-
daily dosing produces a placebo-adjusted trough-to-peak 
ratio that exceeds 50%, then it may be administered once 
daily.10   Antihypertensive agents with lower trough-to-peak 
ratios require multiple daily doses to achieve an acceptable 
  trough-to-peak ratio.3 An agent that has an acceptable 
trough-to-peak ratio for once-daily administration will have 
more uniform BP control   throughout the day compared 
with an agent that has an unacceptable   trough-to-peak ratio 
(Figure 1).11
A higher trough-to-peak ratio indicates a longer dura-
tion of action and may provide a better risk-to-benefit ratio 
through optimal therapeutic coverage during the nighttime 
and early morning hours with fewer adverse events.3,12 
BP control should be maintained in the early morning hours 
in patients with BP rise because the rate of cardiovascular 
events peaks in the morning hours between 6 am and 12 
pm, and the two events are thought to be associated.3,13 In 
a recent 5-year study involving 10 normotensive elderly 
volunteers and 32 elderly patients with well-controlled 
hypertension, a morning surge in systolic BP (SBP) of 
34 mm Hg or more was, independent of both clinic and 
ambulatory BP (ABP), associated with an increased risk of 
cardiovascular events compared with a morning surge in SBP 
of less than 34 mm Hg.14 Therefore, antihypertensive medi-
cations that reduce the extent of the early morning BP rise 
may reduce the vascular risk in patients with   hypertension. 
One analysis illustrates the difference a longer duration of 
action can have on early morning BP rise. A comparison 
of the effect of telmisartan 80 mg once daily (trough-to-
peak ratio of approximately 90%) versus ramipril 10 mg 
once daily (trough-to-peak ratio of approximately 50%) on 
early morning BP rise from the pooled data of two studies 
in patients with hypertension showed that telmisartan was 
associated with a 1.8-mm Hg lesser rise from nadir in SBP 
compared with ramipril.15 Moreover, telmisartan provided 
lower BP values throughout the 24-hour dosing period com-
pared with ramipril in the two studies.16,17 The timing of the 
administration of an antihypertensive agent can affect the 
early morning surge in BP. In 238 patients with untreated 
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Figure 1 Blood pressure responses during a steady-state 24-hour dose interval for 
an agent with an acceptable (75%) trough-to-peak ratio (A) and an agent with an 
unacceptable (45%) trough-to-peak ratio (B).
Note: Adapted with permission from Meredith.11
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hypertension, 8 weeks of bedtime nifedipine gastrointestinal 
therapeutic system (GITS) dosing reduced the morning rise 
in SBP and diastolic BP (DBP) from the nocturnal nadir 
by -6.2 and -4.4 mm Hg, respectively (P , 0.001), while 
the morning nifedipine GITS dose had no such effect.18 
In addition, overall ABP control was higher (43% versus 
28%, P = 0.019) with nighttime dosing versus morning 
dosing;18 however, the effects of nighttime dosing on the 
  trough-to-peak ratio have not been examined.
Patients with hypertension also have larger fluctuations 
in their BP levels throughout the day compared with nor-
motensive individuals.19 Shorter-acting agents may allow 
for greater daytime variations in BP, making the 24-hour 
trough-to-peak ratio difficult to interpret. This was reported 
in a study involving 30 patients treated with felodipine 
10 mg once daily or nifedipine 20 mg twice daily for 
2 weeks.20 The placebo-corrected SBP/DBP trough-to-peak 
ratio was 80%/75% for felodipine. However, nifedipine 
produced a biphasic change in 24-hour BP readings, and 
the   trough-to-peak ratio was not calculated. Although 
both agents produced similar decreases in BP values, 
there were fewer variations in daytime BP as assessed by 
24-hour ABP monitoring with longer-acting felodipine. 
Moreover, an analysis of data from the Anglo-Scandinavian 
Cardiac   Outcomes Trial Blood Pressure Lowering Arm 
(ASCOT-BPLA) trial demonstrated that BP variability 
decreased over time with amlodipine-based treatment 
(5–10 mg; 50%–100% trough-to-peak ratio21) but increased 
with atenolol-based treatment (50–100 mg; 46% trough-
to-peak ratio22).23–25 Large fluctuations in BP throughout the 
day, which may occur with a lower trough-to-peak ratio, 
may therefore be ameliorated with a high trough-to-peak 
ratio once-daily agent.3
In another study by Goyal and colleagues, 29 patients 
were recruited based on the original criteria for the Heart 
  Outcomes Prevention Evaluation (HOPE) study and were 
given ramipril either in twice-daily dose (5 mg bid) or 
once-daily (10 mg q AM) each morning in a randomized, 
prospective cross-over trial.26 Twenty-four hour ABP record-
ings were taken prior to initiation of ramipril therapy and 
after treatment with twice-daily and once-daily ramipril. The 
results showed that ramipril caused a significant reduction 
of BP over a 24-hour period as compared with baseline. The 
mean baseline ABP of 124/73 mm Hg fell to 117/69 mm Hg 
on the twice-a-day regimen (P , 0.001) and to 115/68 mm 
Hg for the daily morning regimen (P , 0.001). There 
was a trend to better 24-hour BP control with once-daily 
dosing as compared with twice-daily dose of ramipril, 
but the difference was not statistically different. Though 
not conclusive, these data suggested slightly better early 
morning (5 am–8 am) BP control with twice-daily than the 
usual once-daily morning dosing.
Nighttime BP normally decreases 10%–20% from 
  daytime values.27 However, up to 50% of patients with 
hypertension may not exhibit this normal reduction in BP.28,29 
In one study of 8384 untreated patients with hypertension, 
35% of the patients were nondippers, 8.8% were classified 
as extreme dippers (nocturnal BP decline . 20%), and 6% 
were classified as risers.29 If the BP percentage change at 
night is on either side of the range considered normal, then a 
patient is considered to have an abnormal diurnal variation.28 
Evidence from clinical trials has shown that the once-daily 
antihypertensive agents verapamil and amlodipine reduce 
nighttime BP in patients who lack a nocturnal BP decrease 
without excessive lowering of nighttime BP in those patients 
with normal or excessive pretreatment nocturnal declines 
in BP.30,31 Alternatively, evening dosing also provides effec-
tive 24-hour BP control while preferentially increasing the 
decline in nocturnal BP in patients with a nondipper status. 
For example, in 90 patients randomized to receive morn-
ing or evening valsartan (160 mg/day), ABP monitoring 
demonstrated similar mean BP reductions between the two 
treatment groups.32 However, the evening valsartan dose 
preferentially lowered nocturnal BP compared with the 
morning dose, which translated into a 73% relative reduction 
in the proportion of patients with nondipper status. In the 
HOPE study, evaluating nighttime ramipril (10 mg/day) 
for 5 years in patients (N = 9297) with hypertension and 
at high risk for cardiovascular events, ABP monitoring in 
38 patients with peripheral arterial disease demonstrated 
a significant improvement in the diurnal–nocturnal ratio 
at 1 year (P , 0.01).33,34 These results suggest that the 
clinical benefits observed in the overall HOPE study may 
be related to the ABP reduction, especially at nighttime. 
Moreover, ramipril reportedly has a relatively smooth effect 
on 24-hour BP among angiotensin-converting enzyme 
inhibitors.33 Therefore, an agent with a high smoothness 
index may not translate to an effective improvement in the 
diurnal–nocturnal ratio. However, a limitation of the HOPE 
study is the lack of a morning comparison group. The 
Monitorizacion Ambulatoria de Presion arterial y Eventos 
Cardiovasculares (MAPEC) study reported great BP control 
rates in patients (N = 2156) with hypertension receiving 
more than one antihypertensive at nighttime versus taking 
all antihypertensive medication upon arising after a mean 
follow-up of 5.6 years.35Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Variations in 24-hour coverage among 
once-daily antihypertensive agents
The therapeutic coverage of once-daily dosing varies 
among antihypertensive agents such that the therapeutic 
effect may be either less than or longer than 24 hours. In 
fact, the   trough-to-peak ratios of individual agents differ 
as much within an antihypertensive drug class as between 
classes.8 The importance of these therapeutic differences 
becomes apparent with mistimed doses. It should be 
noted that the trough-to-peak ratio can be used to evalu-
ate any dosing regimen frequency (eg, for a drug that is 
administered 2 or 3 times daily, as long as the calculated 
trough-to-peak ratio is greater than 50% when the drug 
is dosed at that frequency, the dosing regimen would be 
considered appropriate).
Among the angiotensin receptor blockers, the   trough-to-peak 
ratios for once-daily monotherapy were reported for four 
agents in clinical trials and were all higher than 50%.36–39 The 
trough-to-peak ratio with candesartan cilexetil was shown 
to range from 80% to 100%, whereas the trough-to-peak 
ratio with valsartan was 66%.37,38 The trough-to-peak ratio in 
patients with hypertension was 70% for once-daily losartan 
50 mg compared with 90%–110% for once-daily candesartan 
8 or 16 mg after 8 weeks of treatment.39 In 207 patients treated 
with once-daily telmisartan 40, 80, or 120 mg or enalapril 
20 mg once daily for 28 days, the DBP trough-to-peak ratios 
were 85% or higher for all telmisartan doses and 65% for 
enalapril.40 These studies also showed a positive relationship 
of the dose to the trough-to-peak ratio.
A review of clinical trials using once-daily angiotensin-
converting enzyme inhibitors (24 trials) and calcium   channel 
blockers (34 trials) calculated the trough-to-peak ratios 
among individual agents in these two classes (Table 1).21,41–46 
Among both classes of agents, trough-to-peak ratios ranged, 
in general, from 10% to 80%, with five agents reporting up 
to 100% (perindopril, trandolapril, amlodipine, lacidipine, 
and verapamil).
Only one study has reported the therapeutic coverage of 
the direct renin inhibitor aliskiren. An 8-week study in 355 
elderly patients with hypertension reported that the SBP 
trough-to-peak ratios of aliskiren 75 mg, 150 mg, and 300 mg 
were 77%, 64%, and 79%, respectively.47
The majority of clinical trials conducted with diuretics 
did not include trough-to-peak ratio information.   However, 
one study of pooled data involving 216 patients with 
hypertension provided trough-to-peak ratio information 
for both indapamide sustained release (SR) 1.5 mg once 
daily and immediate release (IR) 2.5 mg once daily.48,49 
Table 1 Diastolic trough-to-peak ratios of angiotensin-converting 
enzyme inhibitors and calcium channel blockers as administered 
once daily
Agent (dose) Average trough-to-peak ratio, %
More than  
50%
50% Less than   
50%
Angiotensin-converting enzyme inhibitors
Perindoprila (2–16 mg) ∼75–100
Fosinopril (20 mg) 64
Ramipril (5 and 10 mg) 50–63
Trandolapril (1 and 2 mg) 50–100
enalapril (5, 10, and 20 mg) 40–64
Benazeprila (20–80 mg) ∼50
Quinaprila (10–80 mg) ∼50
Lisinopril (10–80 mg) 30–70
Captoprilb (25–100 mg) 25
Cilazapril (2.5 and 5.0 mg) 10–80
Calcium channel blockers
Amlodipine (5–10 mg) 50–100
Lacidipine (2–6 mg) 40–100
Nifedipine Coat-Core  
(30 and 60 mg)
50–69
Nifedipine GITS  
(30 and 60 mg)
60–94
Verapamil slow-release  
formulations (240 mg)
45–100
Isradipine slow-release  
formulationsa (5, 10, 15,  
and 20 mg)
76–100
Diltiazem slow-release  
formulations (120, 240,  
300, 360, and 480 mg)
20–80
Felodipine eRa (2.5, 5, 10,  
and 20 mg)
∼40–50
Nitrendipine (10–20 mg) 10–80
Notes: Data from Zannad et al;21 adata from prescribing information;41,43–46 busually 
administered two- or three-times daily, Captopril prescribing information.42
Abbreviations: ER, extended release; GITS, gastrointestinal therapeutic system.
After 2 months of indapamide treatment, the SBP/DBP 
trough-to-peak ratios were 89%/85% for indapamide SR 
and 104%/98% for   indapamide IR. Importantly, this study 
illustrates that a higher dose of a shorter-acting agent can 
achieve an acceptable trough-to-peak ratio. However, this 
is typically not desirable because the incidence of adverse 
events may increase; although in this trial there was no 
difference in adverse events reported between the two 
treatments.
There are many β-adrenergic blocking agents with 
reported trough-to-peak ratios, the majority of which are 
higher than 50% (Table 2).10,22,50–54 Atenolol administered 
once daily had disparate values of trough-to-peak ratios 
reported, probably because of the doses used in each study 
(200 mg/day [104%] versus up to 100 mg/day [46%]).22,50,51 
Metoprolol doses of up to 400 mg/day also had a low Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Missed antihypertensive doses
Effects on BP when an antihypertensive dose is missed or 
mistimed depend on the agent’s total therapeutic   coverage. 
Among the once-daily agents, therapeutic effects may not last 
beyond 24 hours, resulting in loss of BP control   (Figure 2).4 For 
example, in 246 patients treated with once-daily   amlodipine 
(5–10 mg; 50%–100% trough-to-peak ratio21) or once-
daily valsartan (40–80 mg; 66%   trough-to-peak ratio38) for 
12 weeks, a simulated dose omission via single-blind placebo 
dose resulted in a 48-hour gap in dosing.60 Greater control of 
morning BP rise was reported in amlodipine-treated patients 
compared with valsartan-treated patients after 48 hours without 
antihypertensive medication (DBP, P , 0.04; SBP, P = not 
significant).60 In another trial involving 96 patients with hyper-
tension who were treated with once-daily amlodipine 5–10 mg 
(50%–100% trough-to-peak ratio21) or once-daily perindopril 
4–8 mg (35%   trough-to-peak ratio21) for 60 days, BP decreases 
were similar between the treatment groups. However, 48 hours 
after last doses, amlodipine SBP/DBP values were 7.3/4.8 mm 
Hg lower than in the perindopril group (P # 0.05 for SBP 
and DBP).61 A final study comparing once-daily candesartan 
8 and 16 mg (80%–100% trough-to-peak ratio37) with once-
daily losartan 50 and 100 mg (70% trough-to-peak ratio39) 
for 8 weeks in 268 patients with hypertension showed that 
at 48 hours after the last dose, patients receiving candesartan 
had lower mean SBP and DBP compared with those receiving 
losartan (P , 0.001 for both).62
Clinical implications of BP 
variations
BP has a natural diurnal variation that may be altered in 
patients with hypertension.12 In addition to the differences 
in early morning rise and variability throughout the day 
Table 2 Trough-to-peak ratios of β-adrenergic receptor-blocking 
agents
Agent (dose) Trough-to-peak ratio, %
Acebutolol DBP (400–800 mg) 71
Atenolol DBP and MAPa (50–200 mg) 46 and 104a
Bisoprolol MAP (5 mg) 58
Betaxolol SBP/DBP (10 and 20 mg) 73/72
Carvedilol 12-hour MAP (25 mg) 85
Carvedilol CR DBP 
  20 mg/day 
  40 mg/day 
  80 mg/day
 
73 
64 
65
Metoprolol MAP (200, 300, and 400 mg) 44b
Metoprolol tartrate extended-release  
SBP/DBP (100 and 200 mg)
71/67
Nebivolol 
  Overall, 5 mg 
  SBP/DBP, 5 mg
 
91 
72/88
Pindolol MAP (15, 30, and 45 mg) 70
Propranolol, slow-release formulation  
MAP (160, 320, 480, and 640 mg)
107
Notes: Data from Floras et al,50 Kuroedov et al,54 Neutel et al,51 Soucek et al,10 
Stoschitzky et al,52 weber et al,53 and wing;22 a104% was based on 200 mg atenolol 
per day; bbased on once-daily administration.
Abbreviations: CR, controlled release; DBP, diastolic blood pressure; MAP, mean 
arterial pressure; SBP, systolic blood pressure.
Table 3 Trough-to-peak ratios of combination antihypertensive 
therapy
Combination Trough-to-peak ratio, %
Amiloride/HCTZ (2.5/5 mg) versus 
Nifedipine GITS (30 mg), SBP/DBP
50 to .70/50 to .90  
.60 to 80/.55 to 75
Irbesartan/HCTZ (300/25 mg), SBP/DBP 92/84  
97/89 in responders
Losartan/HCTZ (100/25 mg), SBP/DBP 88/86
Losartan/Nifedipine GITS (50/20 mg), DBP 70
Valsartan/HCTZ (80/12.5 mg) versus 
Amlodipine (5, 10 mg), SBP/DBP
61/57 (76/74 in responders) 
56/56 (66/62 in responders)
Note: Data from Coca et al,36 Coca et al,55 Kuschnir et al,56 Mancia et al,57 and 
Palatini et al.58
Abbreviations: DBP, diastolic blood pressure; GITS, gastrointestinal therapeutic 
system; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure.
  trough-to-peak ratio reported in one study (44%); however, 
this value was based on once-daily administration.22,50
A few studies reported trough-to-peak ratios when combi-
nations of antihypertensive agents were used (Table 3).36,55–58 
Valsartan plus hydrochlorothiazide reported a similar trough-
to-peak ratio (61%/57%) as that reported with valsartan alone 
in a previously described study (66%).38,58 Therefore, the 
duration of action was not affected by the addition of another 
agent, although BP was lower with the combination   treatment. 
Moreover, among 20 African-American patients, who are often 
more resistant to hypertension therapies,   valsartan (with hydro-
chlorothiazide added to control BP) had a SBP/DBP trough-to-
peak ratio of 94%/91% after 8–10 weeks of treatment.59
40 30 35 25 20 15 10 5 0
0
–10
–20
–30
–40
Time (hours)
m
m
H
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43% trough:peak 60% trough:peak
Figure 2 Placebo-corrected blood pressure responses beyond a 24-hour dosing 
interval for two antihypertensive agents: one with a high trough-to-peak ratio and 
one with a lower trough-to-peak ratio.
Note: Adapted with permission from Meredith and Elliott.4Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
782
Flack and Nasser
mentioned previously, nighttime BP may not decrease to 
the same extent in patients with hypertension as in nor-
motensive individuals. Clinical studies have reported that 
patients with hypertension who lack a normal nocturnal BP 
pattern have an elevated risk of target organ damage and 
cardiac events compared with hypertensive patients who 
have a normal nocturnal BP decrease.63,64 In fact, nighttime 
BP is a more sensitive prognostic factor for cardiovascular 
mortality risk than ABP monitoring, with a 21% increased 
risk for each 10-mm Hg higher nighttime SBP (P , 0.001) 
and a 9% greater risk for each 5-mm Hg higher nighttime 
DBP (P , 0.01).65 Additionally, in the MAPEC study, over 
median follow-up of 5.6 years, nighttime dosing of one or 
more antihypertensive medications compared with ingestion 
of all antihypertensive medications upon awakening reduced 
the relative risk of total cardiovascular events (P , 0.001) 
and major events (death, myocardial infarction, ischemic 
stroke, and hemorrhagic stroke; P , 0.001) compared with 
patients who received their medication in the morning.35 An 
optimal antihypertensive medication should provide uniform 
24-hour BP control and also bring the diurnal variation closer 
to normal.
Antihypertensive medications that are dosed once daily 
are typically administered in the morning rather than in the 
evening. However, there is a body of data suggesting that 
antihypertensive agents representing several drug classes 
lower BP more effectively at night with no loss of BP control 
during the awake, active daytime hours; in some instances, 
nighttime dosing has been linked to greater overall ambula-
tory BP control. Quinapril, an angiotensin-converting enzyme 
(ACE) inhibitor dosed once daily, either in the   morning 
or evening, lowered BP more effectively throughout the 
24 hour ABP recording when dosed in the evening versus 
the morning.66 Accordingly, evening dosing with quinapril 
causes less pronounced but more sustained reductions in 
plasma ACE inhibition than morning dosing.66 Telmisartan, 
an angiotensin receptor blocker (ARB), dosed in the evening 
more effectively restored the normal nocturnal decline in BP 
with similar overall 24-hour BP lowering efficacy compared 
with morning dosing.67 Both doxazosin, an alpha blocker, 
and sustained release isradipine, a dihydropyridine calcium 
antagonist, when administered in the evening to patients with 
chronic kidney failure and hypertension, normalized nocturnal 
BP more effectively than morning dosing with better overall 
24-hour BP control.68 These data in aggregate suggest that 
usual patterns of dosing once daily antihypertensive agents 
may not optimally lower BP and therefore provide maximum 
protection against cardiovascular disease (CVD).
As previously discussed, high early morning surges 
may increase the risk of cardiovascular events. In a study of 
elderly patients with hypertension, an early morning SBP 
surge (assessed during first 2 hours after waking versus 
  lowest nighttime measurement) of 10 mm Hg was associated 
with a 22% greater risk of stroke independent of 24-hour BP 
levels.69 Other prospective studies report conflicting results, 
with large morning surges associated with a lower overall 
cardiovascular risk, a higher overall cardiovascular risk,70 or 
a higher risk of stroke.71
Oscillations in BP throughout the day may cause, as well 
as be a consequence of, target organ injury.72 BP variability 
increases as BP rises and it may play a role in cardiovascular 
events and the development of target organ damage.72 
A   multivariate analysis of data from 180 patients with suspected 
hypertension showed that awake SBP variability was an 
independent predictor of intima-media thickness (P = 0.015), 
left ventricular mass index (P = 0.028), and microalbuminuria 
(P = 0.01).73 These correlations were independent of mean 
BP levels. Furthermore, in 108 patients with moderate to 
severe hypertension, patients with a low variability in 24-hour 
mean BP had a lower prevalence and severity of target organ 
damage than those in whom the 24-hour mean BP variability 
was high (P , 0.05).74 A multiple regression analysis of data 
from 73 patients with follow-up data for a mean of 7.4 years 
showed that long-term BP variability at the initial evaluation 
was significantly correlated to the magnitude of end-organ 
damage at follow-up (P , 0.05).75
Relationship between adherence  
and number of daily antihypertensive 
doses
Adherence and/or compliance is currently defined as 
the extent to which patients take their medications as 
prescribed.5,76 This definition may include both the correct 
number and the correct timing of doses each day. Adherence 
is usually expressed as a rate; the percentage of prescribed 
medication doses taken over a specified time period.5,76 
Assessments of adherence rate may be direct or indirect: 
direct methods include observation and measurement of 
the agent in blood, and indirect methods include clinical 
response, patient self-reports, pill counts, prescription refill 
rate (medication possession ratio), and electronic medication 
monitoring.5 Each of these assessments has advantages and 
disadvantages regarding accuracy, cost, and convenience. 
However, one of the key reasons for poor BP control is lack 
of patient adherence, and several trials have evaluated adher-
ence and BP control.77 One analysis involving 840 patients Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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with hypertension receiving   antihypertensive   monotherapy 
demonstrated that an adherence of 80% or greater was 
associated with a 45% greater likelihood of achieving BP 
control compared with an adherence less than 80%.78 Another 
analysis of chronic conditions, including hypertension, has 
proposed a rate of 80% as the cutpoint between medication 
adherence and nonadherence based on the rate of hospitaliza-
tions during treatment.79 Additionally, a recent analysis of 
patient self-reports, prescription refill records, and electronic 
monitor data from two studies also concluded that 80% adher-
ence was an appropriate cutpoint because this rate provided a 
balance between sensitivity and specificity for all adherence 
assessments.80
Increased adherence with once-daily 
dosing
Several studies in patients with hypertension have dem-
onstrated that once-daily antihypertensive medications 
achieve increased adherence compared with twice-daily 
or multiple-daily dosing.81–83 In a meta-analysis of eight 
hypertension studies, once-daily dosing was associated 
with greater adherence by 5.7% compared with twice-daily 
dosing (P = 0.026).81 Similar results were obtained from the 
comparison of once-daily dosing and multiple-daily dos-
ing (8.2% difference; P , 0.001). A meta-analysis of 76 
electronic monitoring studies, including 17 hypertension 
studies, showed that the mean dose-taking compliance was 
79% for once-daily doses, 69% for twice-daily doses, 65% 
for 3 daily doses, and 51% for 4 daily doses.82 Once-daily 
dosing was significantly associated with improved compli-
ance compared with 3 daily doses (P = 0.008) and 4 daily 
doses (P , 0.001), although there was no statistical difference 
between once-daily and twice-daily dosing in this analysis. In 
another 6-month hypertension study involving 162 patients 
who were not included in the previous meta-analysis, once-
daily dosing was associated with slightly greater compliance 
compared with twice-daily dosing (98.9% versus 97.5%, 
respectively).83 Although patients in both regimens would 
be considered adherent, there were important differences in 
correct dosing periods favoring once-daily dosing.
Previously, evidence was shown supporting the clinical 
consequences of a missed dose; however, mistimed doses 
may also negatively affect BP control depending on the thera-
peutic coverage of the agent.3 Clinical studies have shown 
that adherence to the correct timing of doses is affected by the 
number of daily doses.82,83 In the previously described study 
involving 162 patients, correct dosing periods were achieved 
by 94.0% of patients in the once-daily medication group and 
only 78.1% of patients in the twice-daily medication group 
(P = 0.0001).83 Therefore, there was a lower proportion of 
patients in the twice-daily group who took their medications 
within the correct time window. The majority of patients 
had incorrect dosing periods attributed to delayed doses 
rather than to missed doses. Once-daily dosing decreased 
the   percentage of delayed doses compared with twice-daily 
dosing (1.8% versus 11.7%, respectively; P = 0.0001), 
whereas the percentage of missed doses was similar (2.6% 
versus 3.3%, respectively; P = 0.06). Once-daily dosing was 
also associated with increased correct dose timing compared 
with multiple daily doses. In the meta-analysis of 76   studies, 
14 studies reported dose timing, and once-daily dosing 
increased the rate of dose-timing compliance compared with 
multiple daily dosing (74% versus 58% for twice daily, 46% 
for 3 times daily, and 40% for 4 times daily).82 Moreover, 
once-daily dosing can increase the percentage of days the 
correct number of doses is taken. Overall, once-daily anti-
hypertensive medications improve all aspects of adherence 
compared with multiple daily doses, which may improve 
clinical outcomes.
Effect of increased adherence  
on BP and clinical outcomes
In hypertension, only a few studies reported on adherence 
and clinical outcomes. In three studies, BP control was 
greater in patient groups that had higher adherence.78,83,84 
Additional analyses in the previously described study involv-
ing 162 patients with hypertension, wherein once-daily and 
twice-daily antihypertensive regimens had adherence greater 
than 80% but the proportion of patients with correct dosing 
periods was lower with the twice-daily regimen, demon-
strated that BP control (,140/90 mm Hg) was achieved in 
41% of patients with once-daily dosing and 27% of patients 
with twice-daily dosing.83 In another trial involving 198 
patients with mild hypertension, adherence of 80% or more 
augmented the reduction in BP reduction by approximately 
7 mm Hg compared with adherence of 79% or less (P , 0.05) 
after 20 weeks of treatment with the twice-daily agent.84 
However, BP reductions reported with a once-daily agent 
were similar regardless of adherence rate, probably because 
delayed or missed doses with the long-acting agent had less 
effect on the office BP assessment. A retrospective claims 
database review of 840 patients with hypertension receiving 
monotherapy showed that 43% of patients with adherence 
of 80% or more achieved BP control (,140/90 mm Hg 
or ,130/85 mm Hg with diabetes) compared with 34% of 
patients with adherence of 50%–79% and 33% of patients Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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with adherence lower than 50%.78 A logistic regression model 
demonstrated that patients in the highest adherence group had 
a 45% greater likelihood of achieving BP control compared 
with patients in the lowest adherence group after adjustment 
for age, gender, and comorbidities (P = 0.026).
Increased adherence to antihypertensive medications 
may also decrease the risk of pressure-related cardiovascular 
complications. In a retrospective database review of 82,320 
patients with newly treated hypertension and no evidence 
of CVD, a medication possession ratio adherence of 80% 
or more was associated with decreased risk of   developing 
chronic heart failure by 11% after 1 year of follow-up com-
pared with adherence less than 80% (P , 0.05).85 The cal-
culated risk was adjusted for age, gender, social assistance, 
diabetes, dyslipidemia, presence of respiratory disease, 
higher chronic disease score, developing a cardiovascular 
condition during follow-up, and use of antidepressants 
or anxiolytic agents. In another retrospective analysis of 
the database involving 83,267 patients with newly treated 
hypertension and no evidence of CVD who were each 
matched by age and duration of follow-up to up to 15 con-
trol patients, a medication possession ratio adherence of 
80% or more associated with decreased risk of developing 
cerebrovascular disease by 22% after 1 year of follow-up 
compared with adherence less than 80% (P , 0.05).86 The 
calculated risk was adjusted for cardiovascular risk factors 
such as adherence to diabetes or dyslipidemia medication, 
occurrence of a cardiovascular event during antihypertensive 
therapy, and hypertension severity (assessed by number of 
antihypertensive agents).
Although further study is needed, the evidence suggests 
that an antihypertensive medication adherence of 80% or 
more appears to improve BP control and decrease the risk of 
developing some of the complications of hypertension.
Central aortic versus brachial BP
DBP and mean BP are relatively constant across the cen-
tral (aortic and carotid) and peripheral (brachial) arterial 
  vasculature. However, because of the phenomena termed 
pressure wave amplification, brachial SBP and pulse pressure 
(PP) is higher than the central SBP and PP. The amplifica-
tion of the central SBP and PP – typically between 10 and 
14 mm Hg – is a consequence of the transmission of the 
forward as well as the reflected pressure waves,87 the latter 
emanating mostly from the small muscular resistance arter-
ies and arterioles; thus, there is greater SBP and PP ampli-
fication in persons with significant anatomic remodeling 
of the resistance   arteries and arterioles as well as in older 
persons who typically have stiff, low compliance arterial 
vasculature.
It is physiologically plausible to hypothesize that central 
BP is more important in determining pressure-related risk for 
cerebral and myocardial disease than brachial BP since the 
level of central pressure is more reflective than brachial artery 
pressure of the pressure load these organs face. There are 
several lines of data that support this hypothesis. In the Strong 
Heart Study, noninvasively determined central PP was more 
related to carotid-intima-media thickness and plaque score as 
well as better predicting 5-year incident CVD than brachial 
artery PP.88 Central pressure is also more closely linked to 
vascular hypertrophy, left ventricular mass, and the magnitude 
of carotid atherosclerosis than brachial artery pressure.88–90 
There are several commercially available devices that allow 
for estimation of central pressure in clinical settings.
Antihypertensive drugs do not all lower peripheral and 
central pressures to the same degree. This may also explain, 
at least in part, why drugs that lower brachial BP by nearly 
identical amounts lower CVD risk differentially. Beta 
  blockers cause less reduction in central aortic SBP relative to 
the reduction in brachial SBP in comparison to ACE inhibi-
tors, ARBs, and calcium antagonists.91–93 Nevertheless, beta 
blockers represent a heterogenous drug class and their effects 
on central pressures may vary as well. Accordingly, atenolol 
actually increased central PP in comparison with both nebiv-
olol, a newer nitric oxide releasing beta blocker, and placebo 
in patients with isolated systolic hypertension.94 The utiliza-
tion of noninvasive estimates of central arterial pressures 
represents an exciting paradigm shift that may ultimately 
alter the approach to the selection of antihypertensive agents 
and thus lead to greater CVD risk protection. The results of 
rigorous, prospective, randomized controlled trials will be 
required to validate this intriguing hypothesis.
Conclusion
The number of daily antihypertensive doses affects clinical 
outcomes both directly, through physiologic mechanisms, and 
indirectly, by influencing patients’ abilities to remain adherent 
to their medication regimen. Antihypertensive medications 
should provide 24-hour control while maintaining or restoring 
a normal circadian BP rhythm. Patients need to understand 
the importance of taking their medication according to the 
prescribed regimen.
Once-daily antihypertensive dosing provides favorable 
24-hour BP control compared with multiple daily doses. Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Longer-acting agents may produce more gradual decreases in 
BP at the onset of action and may produce a lower incidence 
of adverse events related to drug action than shorter-acting 
agents. Longer-acting agents may also provide more uniform 
24-hour BP control, providing lower early morning BP rises, 
which may decrease the associated risk for cardiovascular 
events.
Once-daily antihypertensive dosing has been shown to 
have the highest adherence rate compared with multiple-
daily dosing. Increasing the adherence rate to 80% or more 
increases the likelihood of achieving BP control and reduces 
the risk for cardiovascular and cerebrovascular events related 
to disease progression.
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